drugset
drugset / Trial / NCT02514252

Sublingual Fentanyl for the Management of Breakthrough Pain

NCT02514252 ↗

Phase 2 Terminated 6 enrolled M.D. Anderson Cancer Center INSYS Therapeutics Inc · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if an investigational dose of fentanyl sublingual spray (FSS) can help to control pain in patients with advanced cancer when given in an outpatient and inpatient setting.

Timeline

Start
2016-02-02
Primary completion
2019-11-04
Completion
2019-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified — Other

Indications

No indication recorded.